News
SDGR
29.82
+3.65%
1.05
Schrödinger (SDGR) Raises Its 2026 Outlook, Is The Upside Already Priced In?
Simply Wall St · 13h ago
UBS Sticks to Its Hold Rating for Schrodinger (SDGR)
TipRanks · 14h ago
Schrodinger Is Maintained at Buy by TD Cowen
Dow Jones · 1d ago
Schrodinger Price Target Raised to $36.00/Share From $31.00 by TD Cowen
Dow Jones · 1d ago
TD Cowen Maintains Buy on Schrodinger, Raises Price Target to $36
Benzinga · 1d ago
Schrodinger price target raised to $29 from $17 at Morgan Stanley
TipRanks · 1d ago
Schrödinger (SDGR) Q3 2026 Earnings Call Transcript
The Motley Fool · 1d ago
Morgan Stanley Keeps Their Hold Rating on Schrodinger (SDGR)
TipRanks · 1d ago
How Higher Revenue And Narrower Losses Will Impact Schrödinger (SDGR) Investors
Simply Wall St · 1d ago
Schrodinger Q3 2026 Earnings Call Transcript
Benzinga · 2d ago
Schrödinger Clarifies Clinical Study Status and Reports Third-Quarter Results
TipRanks · 2d ago
Schrodinger raises FY26 ACV view to $222M-$232M
TipRanks · 2d ago
*Schrodinger 3Q Rev $64.5M >SDGR
Dow Jones · 2d ago
*Schrodinger 3Q Loss/Shr 50c >SDGR
Dow Jones · 2d ago
SOPHiA GENETICS SA (SOPH) Reports Q3 Loss, Beats Revenue Estimates
NASDAQ · 3d ago
Weekly Report: what happened at SDGR last week (1026-1030)?
Weekly Report · 4d ago
Is Schrödinger (SDGR) Fully Valued As Analyst Upgrades Back Its AI Drug Discovery Story?
Simply Wall St · 10/30 15:34
Private Markets: Claude developer Anthropic files to go public
TipRanks · 10/29 18:36
SDGR Crosses Above Average Analyst Target
NASDAQ · 10/28 10:52
Weekly Report: what happened at SDGR last week (1019-1023)?
Weekly Report · 10/26 09:39
More
Webull provides a variety of real-time SDGR stock news. You can receive the latest news about Schrodinger, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About SDGR
Schrodinger, Inc. is a developer of a physics-based computational platform that enables discovery of molecules for drug development and materials applications. The Company's segments include Software and Drug Discovery. The Software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in the material science industries. The Drug Discovery segment is focused on building a portfolio of preclinical and clinical drug programs, internally and through collaborations. It offers WaterMap, which characterizes the locations and energetics of water molecules occupying the binding site of, or solvating, a target protein. It also offers FEP+, which is a free energy calculation software which can be used to replace the central core of earlier known tight binding molecules to identify potent molecules unavailable in library collections. It can also be used to calculate absolute binding affinities.